【摘要】 目的探讨阿司匹林及氯吡格雷双联抗血小板治疗后循环缺血性脑卒中(PCIS)的临床疗效。方法选择2015年7月～2017年7月我院收治的126例PCIS患者,按照治疗方法的不同分为对照组(63例,阿司匹林)和观察组(63例,阿司匹林及氯吡格雷),观察并比较两组的美国国立卫生研究院卒中量表(NIHSS)评分、阿尔茨海默症评估量表(ADAS-Cog)评分、凝血指标、血液流变学指标及不良反应的差异。并在随访1年后,比较两组患者的不良预后的差异。结果两组患者治疗后的NIHSS评分、ADAS-Cog评分、PLT、FIB水平及全血黏度水平均显著降低(P<0.05),且观察组的上述指标均显著低于对照组(P<0.05)。随访1年后,观察组总不良预后发生率显著低于对照组(P<0.05)。结论双联抗血小板治疗有助于提高PCIS患者的临床疗效,改善神经功能及预后,且具有良好安全性,临床可推荐应用。更多还原

【Abstract】 Objective To investigate the clinical efficacy of aspirin and clopidogrel dual antiplatelet regimen in the treatment of posterior circulation ischemic stroke(PCIS). Methods A total of 126 patients with PCIS admitted in our hospital from July 2015 to July 2017 were enrolled and divided into the control group(63 patients, aspirin) and the observation group(63 patients, aspirin and clopidogrel). The differences between the National Institutes of Health Stroke Scale(NIHSS) score, the Alzheimer’s Disease Assessment Scale(ADAS-Cog) score, coagulation parameters, hemorheology,and adverse events were observed and compared between the two groups. After 1 year of follow-up, the differences in poor prognosis between the two groups were compared. Results The NIHSS score, ADAS-Cog score, PLT, FIB level and whole blood viscosity level of the two groups were significantly lower after treatment(P<0.05), and the above indexes of the observation group were significantly lower than those of the control group(P<0.05). After 1 year of follow-up,the incidence of total adverse prognosis in the observation group was significantly lower than that in the control group(P<0.05). Conclusion Dual antiplatelet therapy can improve the clinical efficacy, neurological function and prognosis of patients with PCIS, which has good safety and can be recommended for clinical application.更多还原